CatherineSibyl(Magid)DiefenbachMD

PubMed

• 90 citations
  A genome-scale screen for synthetic drivers of T cell proliferation.
  Mateusz Legut, Zoran Gajic, Maria Guarino, Zharko Daniloski, Jahan A Rahman
  Nature. 2022-03-01
• 4 citations
  Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
  Richard J. Lin, Catherine Diefenbach
  Oncology. 2016-10-15
• 3 citations
  Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
  Sanjal H Desai, Michael A Spinner, Andrew M Evens, Alice Sykorova, Veronika Bachanova
  Blood Advances. 2023-12-12

Journal Articles

• Ipilimumab, Nivolumab, and Brentuximab Vedotin Combination Therapies in Patients with Relapsed or Refractory Hodgkin Lymphoma: Phase 1 Results of an Open-Label, Multic...  
  Catherine (Magid) Diefenbach, MD, The Lancet Haematology
• CART19 in Hodgkin Lymphoma: Are We Driving the Right Model?  
  Catherine (Magid) Diefenbach, MD, Blood

Abstracts/Posters

• Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0407
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  Catherine Diefenbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicit... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a p... 
  2019 ASCO Annual Meeting - 6/1/2019
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Beyond Transplant: Novel Therapies in Relapsed Hodgkin Lymphoma 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
• Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all